CHAPTER 1. METHODOLOGY AND SCOPE
1.1. MARKET SEGMENTATION & SCOPE
1.2. MARKET DEFINITIONS
1.2.1. PRODUCT & SERVICE SEGMENT
1.2.2. TYPE SEGMENT
1.2.3. WORKFLOW SEGMENT
1.2.4. APPLICATION SEGMENT
1.2.5. END USE SEGMENT
1.3. INFORMATION ANALYSIS
1.3.1. MARKET FORMULATION & DATA VISUALIZATION
1.4. DATA VALIDATION & PUBLISHING
1.5. INFORMATION PROCUREMENT
1.5.1. PRIMARY RESEARCH
1.6. INFORMATION OR DATA ANALYSIS
1.7. MARKET FORMULATION & VALIDATION
1.8. MARKET MODEL
1.9. OBJECTIVES
CHAPTER 2. EXECUTIVE SUMMARY
2.1. MARKET SNAPSHOT
2.2. SEGMENT SNAPSHOT
2.3. COMPETITIVE LANDSCAPE SNAPSHOT
CHAPTER 3. MARKET VARIABLES, TRENDS, & SCOPE
3.1. MARKET LINEAGE OUTLOOK
3.1.1. PARENT MARKET OUTLOOK
3.1.2. RELATED/ANCILLARY MARKET OUTLOOK
3.2. MARKET DYNAMICS
3.2.1. RISING PREVALENCE OF INHERITED DISORDERS
3.2.2. DECREASING COSTS FOR GENETIC SEQUENCING
3.2.3. RISING DEMAND FOR WHOLE GENOME SEQUENCING FOR GENOME MAPPING PROGRAMS
3.3. MARKET RESTRAINT ANALYSIS
3.3.1. ETHICAL AND LEGAL CHALLENGES ASSOCIATED WITH GENOMIC SEQUENCING
3.4. INDUSTRY ANALYSIS TOOLS
3.4.1. PORTER'S FIVE FORCES ANALYSIS
3.4.2. MACROECONOMIC ANALYSIS
3.4.3. COVID-19 IMPACT ANALYSIS
CHAPTER 4. WHOLE GENOME SEQUENCING MARKET: PRODUCT & SERVICE BUSINESS ANALYSIS
4.1. PRODUCT & SERVICE SEGMENT DASHBOARD
4.2. GLOBAL WHOLE GENOME SEQUENCING MARKET: PRODUCT & SERVICE MOVEMENT ANALYSIS
4.3. GLOBAL WHOLE GENOME SEQUENCING MARKET SIZE & TREND ANALYSIS, BY PRODUCT & SERVICE, 2018 TO 2030 (USD MILLION)
4.4. INSTRUMENTS
4.4.1. INSTRUMENTS MARKET, 2025 - 2033
4.5. CONSUMABLES
4.5.1. CONSUMABLES MARKET, 2025 - 2033
4.6. SERVICES
4.6.1. SERVICES MARKET, 2025 - 2033
CHAPTER 5. WHOLE GENOME SEQUENCING MARKET: TYPE BUSINESS ANALYSIS
5.1. TYPE SEGMENT DASHBOARD
5.2. GLOBAL WHOLE GENOME SEQUENCING MARKET: TYPE MOVEMENT ANALYSIS
5.3. GLOBAL WHOLE GENOME SEQUENCING MARKET SIZE & TREND ANALYSIS, BY TYPE, 2018 TO 2030 (USD MILLION)
5.4. LARGE WHOLE GENOME SEQUENCING
5.4.1. LARGE WHOLE GENOME SEQUENCING MARKET, 2025 - 2033
5.5. SMALL WHOLE GENOME SEQUENCING
5.5.1. SMALL WHOLE GENOME SEQUENCING MARKET, 2025 - 2033
CHAPTER 6. WHOLE GENOME SEQUENCING MARKET: WORKFLOW BUSINESS ANALYSIS
6.1. WORKFLOW SEGMENT DASHBOARD
6.2. GLOBAL WHOLE GENOME SEQUENCING MARKET: WORKFLOW MOVEMENT ANALYSIS
6.3. GLOBAL WHOLE GENOME SEQUENCING MARKET SIZE & TREND ANALYSIS, BY WORKFLOW, 2018 TO 2030 (USD MILLION)
6.4. PRE-SEQUENCING
6.4.1. PRE-SEQUENCING MARKET, 2025 - 2033
6.5. SEQUENCING
6.5.1. SEQUENCING MARKET, 2025 - 2033
6.6. DATA ANALYSIS
6.6.1. DATA ANALYSIS MARKET, 2025 - 2033
CHAPTER 7. WHOLE GENOME SEQUENCING MARKET: APPLICATION BUSINESS ANALYSIS
7.1. APPLICATION SEGMENT DASHBOARD
7.2. GLOBAL WHOLE GENOME SEQUENCING MARKET: APPLICATION MOVEMENT ANALYSIS
7.3. GLOBAL WHOLE GENOME SEQUENCING MARKET SIZE & TREND ANALYSIS, BY APPLICATION, 2018 TO 2030 (USD MILLION)
7.4. HUMAN WHOLE GENOME SEQUENCING
7.4.1. HUMAN WHOLE GENOME SEQUENCING MARKET, 2025 - 2033
7.5. PLANT WHOLE EXOME SEQUENCING
7.5.1. PLANT WHOLE EXOME SEQUENCING MARKET, 2025 - 2033
7.6. ANIMAL WHOLE EXOME SEQUENCING
7.6.1. ANIMAL WHOLE EXOME SEQUENCING MARKET, 2025 - 2033
7.7. MICROBIAL WHOLE EXOME SEQUENCING
7.7.1. MICROBIAL MARKET, 2025 - 2033
CHAPTER 8. WHOLE GENOME SEQUENCING MARKET: END USE BUSINESS ANALYSIS
8.1. END USE SEGMENT DASHBOARD
8.2. GLOBAL WHOLE GENOME SEQUENCING MARKET: END USE MOVEMENT ANALYSIS
8.3. GLOBAL WHOLE GENOME SEQUENCING MARKET SIZE & TREND ANALYSIS, BY END USE, 2018 TO 2030 (USD MILLION)
8.4. ACADEMIC & RESEARCH INSTITUTES
8.4.1. ACADEMIC & RESEARCH INSTITUTES MARKET, 2025 - 2033
8.5. HOSPITALS & CLINICS
8.5.1. HOSPITALS & CLINICS MARKET, 2025 - 2033
8.6. PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
8.6.1. PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET, 2025 - 2033
8.7. OTHERS
8.7.1. OTHERS MARKET, 2025 - 2033
CHAPTER 9. WHOLE GENOME SEQUENCING MARKET: REGIONAL BUSINESS ANALYSIS
9.1. REGIONAL DASHBOARD
9.2. MARKET SIZE & FORECASTS AND TREND ANALYSIS, 2018 TO 2030
9.3. NORTH AMERICA
9.3.1. NORTH AMERICA WHOLE GENOME SEQUENCING MARKET, 2025 - 2033
9.3.2. U.S.
9.3.2.1. KEY COUNTRY DYNAMICS
9.3.2.2. TARGET DISEASE PREVALENCE
9.3.2.3. COMPETITIVE SCENARIO
9.3.2.4. REGULATORY FRAMEWORK
9.3.2.5. REIMBURSEMENT SCENARIO
9.3.2.6. U.S. WHOLE GENOME SEQUENCING MARKET, 2025 - 2033
9.3.3. CANADA
9.3.3.1. KEY COUNTRY DYNAMICS
9.3.3.2. TARGET DISEASE PREVALENCE
9.3.3.3. COMPETITIVE SCENARIO
9.3.3.4. REGULATORY FRAMEWORK
9.3.3.5. REIMBURSEMENT SCENARIO
9.3.3.6. CANADA WHOLE GENOME SEQUENCING MARKET, 2025 - 2033
9.3.4. MEXICO
9.3.4.1. KEY COUNTRY DYNAMICS
9.3.4.2. TARGET DISEASE PREVALENCE
9.3.4.3. COMPETITIVE SCENARIO
9.3.4.4. REGULATORY FRAMEWORK
9.3.4.5. REIMBURSEMENT SCENARIO
9.3.4.6. MEXICO WHOLE GENOME SEQUENCING MARKET, 2025 - 2033
9.4. EUROPE
9.4.1. EUROPE WHOLE GENOME SEQUENCING MARKET, 2025 - 2033
9.4.2. GERMANY
9.4.2.1. KEY COUNTRY DYNAMICS
9.4.2.2. TARGET DISEASE PREVALENCE
9.4.2.3. COMPETITIVE SCENARIO
9.4.2.4. REGULATORY FRAMEWORK
9.4.2.5. REIMBURSEMENT SCENARIO
9.4.2.6. GERMANY WHOLE GENOME SEQUENCING MARKET, 2025 - 2033
9.4.3. UK
9.4.3.1. KEY COUNTRY DYNAMICS
9.4.3.2. TARGET DISEASE PREVALENCE
9.4.3.3. COMPETITIVE SCENARIO
9.4.3.4. REGULATORY FRAMEWORK
9.4.3.5. REIMBURSEMENT SCENARIO
9.4.3.6. UK WHOLE GENOME SEQUENCING MARKET, 2025 - 2033
9.4.4. FRANCE
9.4.4.1. KEY COUNTRY DYNAMICS
9.4.4.2. TARGET DISEASE PREVALENCE
9.4.4.3. COMPETITIVE SCENARIO
9.4.4.4. REGULATORY FRAMEWORK
9.4.4.5. REIMBURSEMENT SCENARIO
9.4.4.6. FRANCE WHOLE GENOME SEQUENCING MARKET, 2025 - 2033
9.4.5. ITALY
9.4.5.1. KEY COUNTRY DYNAMICS
9.4.5.2. TARGET DISEASE PREVALENCE
9.4.5.3. COMPETITIVE SCENARIO
9.4.5.4. REGULATORY FRAMEWORK
9.4.5.5. REIMBURSEMENT SCENARIO
9.4.5.6. ITALY WHOLE GENOME SEQUENCING MARKET, 2025 - 2033
9.4.6. SPAIN
9.4.6.1. KEY COUNTRY DYNAMICS
9.4.6.2. TARGET DISEASE PREVALENCE
9.4.6.3. COMPETITIVE SCENARIO
9.4.6.4. REGULATORY FRAMEWORK
9.4.6.5. REIMBURSEMENT SCENARIO
9.4.6.6. SPAIN WHOLE GENOME SEQUENCING MARKET, 2025 - 2033
9.4.7. DENMARK
9.4.7.1. KEY COUNTRY DYNAMICS
9.4.7.2. TARGET DISEASE PREVALENCE
9.4.7.3. COMPETITIVE SCENARIO
9.4.7.4. REGULATORY FRAMEWORK
9.4.7.5. REIMBURSEMENT SCENARIO
9.4.7.6. DENMARK WHOLE GENOME SEQUENCING MARKET, 2025 - 2033
9.4.8. SWEDEN
9.4.8.1. KEY COUNTRY DYNAMICS
9.4.8.2. TARGET DISEASE PREVALENCE
9.4.8.3. COMPETITIVE SCENARIO
9.4.8.4. REGULATORY FRAMEWORK
9.4.8.5. REIMBURSEMENT SCENARIO
9.4.8.6. SWEDEN WHOLE GENOME SEQUENCING MARKET, 2025 - 2033
9.4.9. NORWAY
9.4.9.1. KEY COUNTRY DYNAMICS
9.4.9.2. TARGET DISEASE PREVALENCE
9.4.9.3. COMPETITIVE SCENARIO
9.4.9.4. REGULATORY FRAMEWORK
9.4.9.5. REIMBURSEMENT SCENARIO
9.4.9.6. NORWAY WHOLE GENOME SEQUENCING MARKET, 2025 - 2033
9.5. ASIA PACIFIC
9.5.1. ASIA PACIFIC WHOLE GENOME SEQUENCING MARKET, 2025 - 2033
9.5.2. JAPAN
9.5.2.1. KEY COUNTRY DYNAMICS
9.5.2.2. TARGET DISEASE PREVALENCE
9.5.2.3. COMPETITIVE SCENARIO
9.5.2.4. REGULATORY FRAMEWORK
9.5.2.5. REIMBURSEMENT SCENARIO
9.5.2.6. JAPAN WHOLE GENOME SEQUENCING MARKET, 2025 - 2033
9.5.3. CHINA
9.5.3.1. KEY COUNTRY DYNAMICS
9.5.3.2. TARGET DISEASE PREVALENCE
9.5.3.3. COMPETITIVE SCENARIO
9.5.3.4. REGULATORY FRAMEWORK
9.5.3.5. REIMBURSEMENT SCENARIO
9.5.3.6. CHINA WHOLE GENOME SEQUENCING MARKET, 2025 - 2033
9.5.4. INDIA
9.5.4.1. KEY COUNTRY DYNAMICS
9.5.4.2. TARGET DISEASE PREVALENCE
9.5.4.3. COMPETITIVE SCENARIO
9.5.4.4. REGULATORY FRAMEWORK
9.5.4.5. REIMBURSEMENT SCENARIO
9.5.4.6. INDIA WHOLE GENOME SEQUENCING MARKET, 2025 - 2033
9.5.5. SOUTH KOREA
9.5.5.1. KEY COUNTRY DYNAMICS
9.5.5.2. TARGET DISEASE PREVALENCE
9.5.5.3. COMPETITIVE SCENARIO
9.5.5.4. REGULATORY FRAMEWORK
9.5.5.5. REIMBURSEMENT SCENARIO
9.5.5.6. SOUTH KOREA WHOLE GENOME SEQUENCING MARKET, 2025 - 2033
9.5.6. AUSTRALIA
9.5.6.1. KEY COUNTRY DYNAMICS
9.5.6.2. TARGET DISEASE PREVALENCE
9.5.6.3. COMPETITIVE SCENARIO
9.5.6.4. REGULATORY FRAMEWORK
9.5.6.5. REIMBURSEMENT SCENARIO
9.5.6.6. AUSTRALIA WHOLE GENOME SEQUENCING MARKET, 2025 - 2033
9.5.7. THAILAND
9.5.7.1. KEY COUNTRY DYNAMICS
9.5.7.2. TARGET DISEASE PREVALENCE
9.5.7.3. COMPETITIVE SCENARIO
9.5.7.4. REGULATORY FRAMEWORK
9.5.7.5. REIMBURSEMENT SCENARIO
9.5.7.6. THAILAND WHOLE GENOME SEQUENCING MARKET, 2025 - 2033
9.6. LATIN AMERICA
9.6.1. LATIN AMERICA WHOLE GENOME SEQUENCING MARKET, 2025 - 2033
9.6.2. BRAZIL
9.6.2.1. KEY COUNTRY DYNAMICS
9.6.2.2. TARGET DISEASE PREVALENCE
9.6.2.3. COMPETITIVE SCENARIO
9.6.2.4. REGULATORY FRAMEWORK
9.6.2.5. REIMBURSEMENT SCENARIO
9.6.2.6. BRAZIL WHOLE GENOME SEQUENCING MARKET, 2025 - 2033
9.6.3. ARGENTINA
9.6.3.1. KEY COUNTRY DYNAMICS
9.6.3.2. TARGET DISEASE PREVALENCE
9.6.3.3. COMPETITIVE SCENARIO
9.6.3.4. REGULATORY FRAMEWORK
9.6.3.5. REIMBURSEMENT SCENARIO
9.6.3.6. ARGENTINA WHOLE GENOME SEQUENCING MARKET, 2025 - 2033
9.7. MEA
9.7.1. MEA WHOLE GENOME SEQUENCING MARKET, 2025 - 2033
9.7.2. SOUTH AFRICA
9.7.2.1. KEY COUNTRY DYNAMICS
9.7.2.2. TARGET DISEASE PREVALENCE
9.7.2.3. COMPETITIVE SCENARIO
9.7.2.4. REGULATORY FRAMEWORK
9.7.2.5. REIMBURSEMENT SCENARIO
9.7.2.6. SOUTH AFRICA WHOLE GENOME SEQUENCING MARKET, 2025 - 2033
9.7.3. SAUDI ARABIA
9.7.3.1. KEY COUNTRY DYNAMICS
9.7.3.2. TARGET DISEASE PREVALENCE
9.7.3.3. COMPETITIVE SCENARIO
9.7.3.4. REGULATORY FRAMEWORK
9.7.3.5. REIMBURSEMENT SCENARIO
9.7.3.6. SAUDI ARABIA WHOLE GENOME SEQUENCING MARKET, 2025 - 2033
9.7.4. UAE
9.7.4.1. KEY COUNTRY DYNAMICS
9.7.4.2. TARGET DISEASE PREVALENCE
9.7.4.3. COMPETITIVE SCENARIO
9.7.4.4. REGULATORY FRAMEWORK
9.7.4.5. REIMBURSEMENT SCENARIO
9.7.4.6. UAE WHOLE GENOME SEQUENCING MARKET, 2025 - 2033
9.7.5. KUWAIT
9.7.5.1. KEY COUNTRY DYNAMICS
9.7.5.2. TARGET DISEASE PREVALENCE
9.7.5.3. COMPETITIVE SCENARIO
9.7.5.4. REGULATORY FRAMEWORK
9.7.5.5. REIMBURSEMENT SCENARIO
9.7.5.6. KUWAIT WHOLE GENOME SEQUENCING MARKET, 2025 - 2033
CHAPTER 10. COMPETITIVE LANDSCAPE
10.1. PARTICIPANT CATEGORIZATION
10.2. STRATEGY MAPPING
10.3. COMPANY MARKET POSITION ANALYSIS, 2024
10.4. PARTICIPANT’S OVERVIEW
10.4.1. ILLUMINA, INC.
10.4.1.1. OVERVIEW
10.4.1.2. FINANCIAL PERFORMANCE (NET REVENUE/SALES/EBITDA/GROSS PROFIT)
10.4.1.3. PRODUCT & SERVICE BENCHMARKING
10.4.1.4. STRATEGIC INITIATIVES
10.4.2. THERMO FISHER SCIENTIFIC, INC.
10.4.2.1. OVERVIEW
10.4.2.2. FINANCIAL PERFORMANCE (NET REVENUE/SALES/EBITDA/GROSS PROFIT)
10.4.2.3. PRODUCT & SERVICE BENCHMARKING
10.4.2.4. STRATEGIC INITIATIVES
10.4.3. OXFORD NANOPORE TECHNOLOGIES
10.4.3.1. OVERVIEW
10.4.3.2. FINANCIAL PERFORMANCE (NET REVENUE/SALES/EBITDA/GROSS PROFIT)
10.4.3.3. PRODUCT & SERVICE BENCHMARKING
10.4.3.4. STRATEGIC INITIATIVES
10.4.4. PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
10.4.4.1. OVERVIEW
10.4.4.2. FINANCIAL PERFORMANCE (NET REVENUE/SALES/EBITDA/GROSS PROFIT)
10.4.4.3. PRODUCT & SERVICE BENCHMARKING
10.4.4.4. STRATEGIC INITIATIVES
10.4.5. BGI
10.4.5.1. OVERVIEW
10.4.5.2. FINANCIAL PERFORMANCE (NET REVENUE/SALES/EBITDA/GROSS PROFIT)
10.4.5.3. PRODUCT & SERVICE BENCHMARKING
10.4.5.4. STRATEGIC INITIATIVES
10.4.6. QIAGEN
10.4.6.1. OVERVIEW
10.4.6.2. FINANCIAL PERFORMANCE (NET REVENUE/SALES/EBITDA/GROSS PROFIT)
10.4.6.3. PRODUCT & SERVICE BENCHMARKING
10.4.6.4. STRATEGIC INITIATIVES
10.4.7. AGILENT TECHNOLOGIES
10.4.7.1. OVERVIEW
10.4.7.2. FINANCIAL PERFORMANCE (NET REVENUE/SALES/EBITDA/GROSS PROFIT)
10.4.7.3. PRODUCT & SERVICE BENCHMARKING
10.4.7.4. STRATEGIC INITIATIVES
10.4.8. PROPHASE LABS, INC. (NEBULA GENOMICS)
10.4.8.1. OVERVIEW
10.4.8.2. FINANCIAL PERFORMANCE (NET REVENUE/SALES/EBITDA/GROSS PROFIT)
10.4.8.3. PRODUCT & SERVICE BENCHMARKING
10.4.8.4. STRATEGIC INITIATIVES
10.4.9. PSOMAGEN
10.4.9.1. OVERVIEW
10.4.9.2. FINANCIAL PERFORMANCE (NET REVENUE/SALES/EBITDA/GROSS PROFIT)
10.4.9.3. PRODUCT & SERVICE BENCHMARKING
10.4.9.4. STRATEGIC INITIATIVES
10.4.10. AZENTA US, INC. (GENEWIZ)
10.4.10.1. OVERVIEW
10.4.10.2. FINANCIAL PERFORMANCE (NET REVENUE/SALES/EBITDA/GROSS PROFIT)
10.4.10.3. PRODUCT & SERVICE BENCHMARKING
10.4.10.4. STRATEGIC INITIATIVES
著作権 ©2022 無断複写・転載を禁じます
